These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18704978)

  • 1. Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments.
    Berlin HA; Hamilton H; Hollander E
    Mt Sinai J Med; 2008; 75(3):174-203. PubMed ID: 18704978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.
    Kochan LD; Qureshi AI; Fallon BA
    Curr Psychiatry Rep; 2000 Aug; 2(4):327-34. PubMed ID: 11122977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and potential pharmacological treatments for obsessive-compulsive disorder.
    Davidson J; Bjorgvinsson T
    Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.
    Husted DS; Shapira NA
    CNS Spectr; 2004 Nov; 9(11):833-47. PubMed ID: 15520607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessive-Compulsive Disorder: Puzzles and Prospects.
    Robbins TW; Vaghi MM; Banca P
    Neuron; 2019 Apr; 102(1):27-47. PubMed ID: 30946823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings.
    Nakao T; Okada K; Kanba S
    Psychiatry Clin Neurosci; 2014 Aug; 68(8):587-605. PubMed ID: 24762196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on obsessive-compulsive disorder.
    Jenike MA
    Bull Menninger Clin; 2001; 65(1):4-25. PubMed ID: 11280957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromodulation for obsessive-compulsive disorder.
    Lapidus KA; Stern ER; Berlin HA; Goodman WK
    Neurotherapeutics; 2014 Jul; 11(3):485-95. PubMed ID: 24981434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
    Grados MA; Riddle MA
    J Clin Child Psychol; 2001 Mar; 30(1):67-79. PubMed ID: 11294079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromodulation for obsessive-compulsive disorder.
    Aronson JP; Katnani HA; Eskandar EN
    Neurosurg Clin N Am; 2014 Jan; 25(1):85-101. PubMed ID: 24262902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hazari N; Narayanaswamy JC; Arumugham SS
    Expert Rev Neurother; 2016 Oct; 16(10):1175-91. PubMed ID: 27282021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.
    Fineberg NA; Reghunandanan S; Simpson HB; Phillips KA; Richter MA; Matthews K; Stein DJ; Sareen J; Brown A; Sookman D;
    Psychiatry Res; 2015 May; 227(1):114-25. PubMed ID: 25681005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromodulation in obsessive-compulsive disorder.
    Bais M; Figee M; Denys D
    Psychiatr Clin North Am; 2014 Sep; 37(3):393-413. PubMed ID: 25150569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial.
    Pallanti S; Marras A; Salerno L; Makris N; Hollander E
    J Psychopharmacol; 2016 Jun; 30(6):568-78. PubMed ID: 26843373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.